#FLAURA2: Early ctDNA clearance didn’t identify who could forgo chemotherapy—PFS favored osimertinib + chemo regardless of week 1–2 clearance. Similar clearance rates, different outcomes. Exploratory, but clinically relevant! #ESMO26 @Larvol @myESMO @OncoAlert
10 views · 0 likes · 0 reposts · 0 replies
FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)
https://esmocongress.esmo.orgPACE-LUNG: A multicenter, single-arm, phase II clinical trial evaluating the efficacy of additional chemotherapy for patients with EGFRm NSCLC with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line
https://esmocongress.esmo.orgSource: Elvina Almuradova · x.com